A Study of Eptinezumab in Pediatric Participants With Episodic Migraine
NCT05897320
This study is recruiting at 9 US sites in 6 states, according to its ClinicalTrials.gov record last updated .
Summary
The main goal of this trial is to learn whether eptinezumab helps reduce the number of days with episodic migraine in pediatric participants.
Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov
Conditions studied
- Episodic Migraine
Eligibility basics and study details
- Study type
- Interventional
- Phase
- Phase 3
- Ages
- 6 to 17 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Sponsor
- H. Lundbeck A/S
- Last updated on ClinicalTrials.gov
- October 14, 2026
These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.
US recruiting sites
Connecticut · 1
- New England Institute for Clinical Research (NEICR) - Stamford · Stamford, CT
Florida · 3
- Child Neurology Center (CNC) of Northwest Florida · Gulf Breeze, FL
- AGA Clinical Trials · Hialeah, FL
- University of South Florida (USF) - Tampa Campus · Tampa, FL
Ohio · 2
- Akron Children's Hospital · Akron, OH
- Cincinnati Children's Hospital Medical Center-Burnet Campus · Cincinnati, OH
Texas · 1
- Road Runner Research (RRR) · San Antonio, TX
Virginia · 1
- Children's Specialty Group (CSG) · Norfolk, VA
Wisconsin · 1
- Children's Wisconsin (Children's Hospital of Wisconsin)-Main Campus · Milwaukee, WI
Source: ClinicalTrials.gov, data processed . Recruiting US sites filtered by distance and site status; summaries shortened.